Common
Pelacarsen
Experimental antisense oligonucleotide drug for lowering lipoprotein(a)
Pelacarsen
Pelacarsen is an experimental antisense oligonucleotide drug designed to lower lipoprotein(a) (Lp(a)) levels in patients with cardiovascular disease. The drug targets the LPA gene that encodes apolipoprotein(a), a key component of lipoprotein(a). It was developed by Ionis Pharmaceuticals and Novartis. As of August 2025, pelacarsen is undergoing Phase 3 clinical trials to evaluate its efficacy in reducing major cardiovascular events in patients with established cardiovascular disease and elevated Lp(a) levels. In September 2026, Novartis declared the drug had failed in clinical trials, to the shock of leading physicians, including Harlan Krumholz.
Open boosters, collect cards and trade them. Free to play.
Play for free